LIGAND PHARMACEUTICALS INCORPORATED
NASDAQ: LGND (Ligand Pharmaceuticals Incorpor)
Last update: 12 hours ago303.53
-4.29 (-1.39%)
| Previous Close | 307.82 |
| Open | 307.82 |
| Volume | 366,502 |
| Avg. Volume (3M) | 245,192 |
| Market Cap | 6,051,055,104 |
| Price / Earnings (TTM) | 31.98 |
| Price / Earnings (Forward) | 24.81 |
| Price / Sales | 22.05 |
| Price / Book | 6.16 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2026 |
| Profit Margin | -73.07% |
| Operating Margin (TTM) | -80.87% |
| Diluted EPS (TTM) | -7.29 |
| Quarterly Revenue Growth (YOY) | 46.30% |
| Total Debt/Equity (MRQ) | 0.56% |
| Current Ratio (MRQ) | 5.27 |
| Operating Cash Flow (TTM) | 52.87 M |
| Levered Free Cash Flow (TTM) | 63.35 M |
| Return on Assets (TTM) | -1.14% |
| Return on Equity (TTM) | -16.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Ligand Pharmaceuticals Incorpor | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 2.00 |
Select this tab to load the latest available analysis.
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.35% |
| % Held by Institutions | 100.00% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Chicago Capital, Llc | 30 Sep 2026 | 551,225 |
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |